Soluble form of the endothelial adhesion molecule CD146 binds preferentially CD16+ monocytes
- 5 February 2012
- journal article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (6) , 6745-6752
Abstract
The cell adhesion molecule CD146 is normally located at the endothelial cell-to-cell junction and colocalizes with actin cytoskeleton. The soluble form of CD146 (sCD146) has been identified in the endothelial cell supernatant and in normal human plasma, and is increased in pathologic conditions with altered endothelial function. Soluble CD146 binding to monocytes promotes their transendothelial migration, which represents a central step in the development of atherosclerotic plaque. Since peripheral blood monocytes are characterized by a phenotypic and functional heterogeneity, with different transendothelial migration capacity, we hypothesized that monocyte subsets differently bind sCD146. Based on surface CD14 and CD16 expression monocytes were distinguished by flow cytometry (FACS) into three subsets: CD14++/CD16−, CD14++/CD16+ and CD14+/CD16+. CD16+ monocytes have been found to possess higher transendothelial migration ability. FACS analysis on blood monocytes from 30 healthy subjects revealed that higher percentages of CD14++/CD16+ (median, first and third quartile: 2.26, 1.62–3.87) and of CD14+/CD16+ (2.59, 1.28–4.80) were positive for CD146 (both p < 0.01), in comparison to CD14++/CD16− (0.66, 0.47–1.01). Moreover, in vitro treatment of ficoll separated monocytes with recombinant CD146 showed that both CD16+ subsets increased their percentage of CD146-positive events compared to CD16− monocytes (p < 0.01). Soluble CD146 levels were evaluated by ELISA in plasma samples of subjects from our study group and showed a correlation with percentage of CD146-positive CD14+/CD16+ monocyte subset. In this work we have demonstrated that monocyte subsets behave differently with regard to their sCD146 binding activity; because binding of CD146 influences transendothelial migration of monocytes, modulation of monocyte-CD146 interaction may represent a potential target to limit atherosclerotic plaque development.Keywords
This publication has 36 references indexed in Scilit:
- SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subsetBlood, 2011
- Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsetsBlood, 2011
- Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 ReceptorsImmunity, 2010
- Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent processMicrovascular Research, 2009
- The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functionsJournal of Experimental Medicine, 2007
- Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaquesJournal of Clinical Investigation, 2007
- Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditionsImmunobiology, 2004
- Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alterationThrombosis and Haemostasis, 2003
- Identification of the S-Endo 1 Endothelial-Associated AntigenBiochemical and Biophysical Research Communications, 1996
- Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule.Journal of Cell Biology, 1991